Targeting fibrosis, ascites and liver function
Quick answer
Cirrhosis replaces functioning liver tissue with fibrosis. The approach EHL Bio describes uses the patient's own multipotent stem cells injected directly into the hepatic artery so they can support regeneration of damaged liver tissue, with reported reductions in ascites volume and improved liver function. Using autologous cells also lowers immune rejection risk.
The common causes are hepatitis B and C, alcohol and fatty liver disease (MASLD). Treating the cause always matters most: antivirals, complete alcohol cessation, and weight loss in fatty liver.
Hepatic intra-arterial delivery is an interventional radiology procedure performed by a specialist team — not a routine IV drip done in a beauty clinic. Confirm who performs it and where.
Outcomes should be judged on Child-Pugh and MELD scores, albumin, bilirubin, INR and ultrasound-measured ascites — not just a feeling of improvement.
For end-stage cirrhosis, transplantation remains the intervention that truly changes outcomes; patients should be assessed for transplant listing alongside any other option.
Early fibrosis can improve when the cause is removed, but advanced cirrhosis usually does not reverse; the goal is slowing progression and preventing complications.
Bleeding at the catheter site, thrombosis and vessel injury — hence it must be done in a facility with a full interventional team.
Never stop on your own — abruptly stopping hepatitis B antivirals in particular can trigger a severe flare.
No. Continued drinking undoes any treatment effect and accelerates liver decline.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Kidney, liver, heart, lung